Loading stock data…
AVBP
$30.55+0.05 (+0.16%)
After Hours$30.55+0.00 (+0.00%)· Last close Jun 9
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ArriVent BioPharma, Inc. in the Healthcare sector is trading at $30.55 with a market capitalization of $1.4B. Wall Street consensus targets $42.10 (12 analysts), implying a +37.8% move over the next 12 months. The stock is currently near its 52-week high of $33.62, remaining 32.8% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +37.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$30.55
Potential Downside
0%
Whystock Fair Value$30.55
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus12 analysts
Mean target$42.10+37.8%
Range$25.25 – $50.00
Fundamentals
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is fir...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.39B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.52
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-44.83%
Volume
Today's trading volume
355,779
Recent News
A Look At ArriVent BioPharma (AVBP) Valuation After FDA Clears ARR-002 Oncology Candidate
ArriVent BioPharma (AVBP) stock is in focus after the FDA cleared its investigational new drug application for ARR-002, a dual-target antibody drug conjugate for ovarian and endometrial cancers. See our latest analysis for ArriVent BioPharma. Despite a 2.6% 1-day share price return decline and a 7.2% 7-day pullback, ArriVent BioPharma’s 30-day and 90-day share price returns of 14.53% and 31.98%, alongside a 38.70% year to date share price return and 46.08% 1-year total shareholder return,...
Are You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great Choice
Does ArriVent BioPharma, Inc. (AVBP) have what it takes to be a top stock pick for momentum investors? Let's find out.
Are Medical Stocks Lagging AstraZeneca (AZN) This Year?
Here is how Astrazeneca (AZN) and ArriVent BioPharma, Inc. (AVBP) have performed compared to their sector so far this year.
Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet
The mean of analysts' price targets for ArriVent BioPharma, Inc. (AVBP) points to a 72.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Assessing ArriVent BioPharma (AVBP) Valuation After Recent Share Price Momentum And Pipeline Interest
Event driven snapshot of ArriVent BioPharma ArriVent BioPharma (AVBP) shares recently moved following investor attention on its clinical stage oncology pipeline and ongoing trials. This has prompted closer scrutiny of how the stock’s latest price action lines up with its fundamentals. See our latest analysis for ArriVent BioPharma. At a share price of $24.89, ArriVent BioPharma has a 7 day share price return of 16.15% and a 90 day share price return of 19.66%, while the 1 year total...